Using tools requires that the brain is able to control movements

Milan, Italy, 20 April 2009 - Our ability to use objects and tools to perform actions is essential to our daily activities, and it is developed to a level that is unique to our species. In a study performed by a scientific team of the French National Center for Scientific Research (CNRS) and the Paris Descartes University, published by Elsevier in the April 2009 issue of Cortex (www.elsevier.com/locate/cortex), researchers have found that brain-lesioned patients who have difficulties using familiar objects and tools in their usual context (e.g. cutting paper with scissors) may also be impaired at controlling the movement of an object in the context of simpler movements such as pointing at a target.

Patients suffering from apraxia, a neurological syndrome caused by lesions in the left hemisphere of the brain, have difficulties executing complex movements, including tool use gestures. In this study, the authors compared the performance of apraxics to that of other patients suffering from left cerebral lesion but showing no sign of apraxia, on a task requiring them to point at targets with a stick. Apraxics performed significantly worse than control patients, committing larger errors and sometimes failing to anticipate the changes in movement coordination imposed by the use of a long object to point at a target within hand reach.

Apraxia is often thought to be due to a loss in the ability to translate memories of well-learned gestures into a specific sequence of movements. With these new findings, the authors suggest that some of those patients are also impaired in more elementary processes that allow the incorporation of an object as a functional extension of their limb into their body coordination.

The article is "The use of a tool requires its incorporation into the movement: Evidence from stick-pointing in apraxia" by Stéphane Jacobs, Bernard Bussel, Michele Combèaud and Agnès Roby-Brami appears in Cortex, Volume 45, Issue 4 (April 2009), published by Elsevier in Italy. Full text of the article featured above is available to members of the media upon request. Please contact the Elsevier press office, newsroom@elsevier.com. To schedule an interview, contact Dr. Stéphane Jacobs, sjacobs@uoregon.edu.

Cortex is an international journal devoted to the study of cognition and of the relationship between the nervous system and mental processes, particularly as these are reflected in the behaviour of patients with acquired brain lesions, normal volunteers, children with typical and atypical development, and in the activation of brain regions and systems as recorded by functional neuroimaging techniques. It was founded in 1964 by Ennio De Renzi. The Editor in-chief of Cortex is Sergio Della Sala, Professor of Human Cognitive Neuroscience at the University of Edinburgh. Fax: 0131 6513230, e-mail: cortex@ed.ac.uk. Cortex is available online at http://www.sciencedirect.com/science/journal/00109452

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).